The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Recent clinical trial updates for smoldering multiple myeloma
Irene Ghobrial, MD, of the Dana-Farber Cancer Institute, Boston, MA, provides an overview of key updates in the treatment of high-risk smoldering multiple myeloma (SMM), specifically NCT02279394, NCT02916771 and GEM-CESAR (NCT02415413). Dr Ghobrial, speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, reveals the exciting data from these trials, offering a new treatment outlook for SMM, and hopes for better stratification of patients with SMM, notably with the use of genetics.
